Bright Minds Biosciences Inc.

Bright Minds Biosciences shares sold off after the FDA placed the Company's planned Phase 2 BMB-101 epilepsy trial on partial clinical hold, citing mouse toxicity findings. Levi & Korsinsky is investigating potential securities law violations on behalf of investors who lost money Bright Minds Biosciences shares sold off after the FDA placed the Company's planned Phase 2 BMB-101 epilepsy trial on partial clinical hold, citing mouse toxicity findings. Levi & Korsinsky is investigating potential se…

Bright Minds Biosciences' early epilepsy results support further R&D, although small uncontrolled trials still leave some uncertainties about efficacy and safety. DRUG's further studies or protocol changes could become a path past the FDA's recent hold decision. Naturally, that could involve more R&D costs, but in the long run I think DRUG still has a path forward for BMB-101.

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Bright Minds Biosciences (“Bright Minds” or the “Company”) (NASDAQ: DRUG). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired Bright Minds securities, please contact Lauren Molinaro of Kirby McInerney LLP by emai…

Investors who lost money when DRUG shares sold off on the FDA's partial clinical hold for the planned Phase 2 BMB-101 epilepsy trial may have the right to seek recovery, even if they have already sold. NEW YORK, Nov. 3, 2026 /PRNewswire/ -- Shareholders of Bright Minds Biosciences (NASDAQ: DRUG) are holding losses after the stock sold off when the FDA placed the Company's planned Phase 2 BMB-101 epilepsy trial on partial clinical hold.

The FDA cited mouse toxicity findings and insufficient pharmacokinetic and juvenile-toxicity data when it placed Bright Minds' planned Phase 2 BMB-101 epilepsy trial on partial clinical hold. An investigation is underway on behalf of DRUG investors who suffered losses.

NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces that the U.S. Food and Drug Administration (“FDA”) has notified the Company via email that its investigational new drug application (“IND”) for Developmental and Epileptic Encephalopathies (“DEEs”) and related Protocol BMB-101-105 has been placed on a partial clinical hold following the FDA's review. The proposed trial related to this IND is a randomize…

NASHVILLE, Tenn., Oct. 26, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), ("Cumberland" or the "Company") an innovation-focused biopharmaceutical company developing new products for rare diseases, today provided an update on its ifetroban product candidate in development as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy ("DMD").

NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a clinical stage biotechnology company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that it will participate in the Foundation for Prader-Willi Research (FPWR) 2026 Research Symposium, October 7-8, and the P…

NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences:   EVENT: Cantor Global Healthcare Conference 2026   DATE: Wednesday, Septemb…

Does Bright Minds Biosciences Inc. (DRUG) have what it takes to be a top stock pick for momentum investors? Let's find out.

The average of price targets set by Wall Street analysts indicates a potential upside of 97% in Bright Minds Biosciences Inc. (DRUG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The mean of analysts' price targets for Bright Minds Biosciences Inc. (DRUG) points to a 97.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.